• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Subsense adds $10M in funding to support BCI

Subsense adds $10M in funding to support BCI

December 12, 2025 By Sean Whooley

Subsense Logo (1)Subsense announced that it added $10 million in new capital to support its nanoparticle-based brain-computer interface (BCI) platform.

Golden Falcon Capital delivered the investment, which brings the Palo Alto, California-based company’s total funding to $27 million. It emerged from stealth earlier this year with $17 million in funding.

Subsense said the latest funds will support R&D in nanoparticle sensing, in vivo biosafety programs, next-generation nanoparticle design and hardware miniaturization. It joins the ever-growing BCI market, for which analysts have suggested a potential $400 billion market opportunity. (Learn more about BCIs and some of the players in the space HERE.)

The company’s BCI technology delivers targeted stimulation to specific brain regions, aiming to restore motor functions and enhance rehabilitation therapies. Subsense believes the BCI could help users control smartphones and navigate complex machinery. Its real-time brain monitoring capabilities could also provide critical data to aid in the early detection and understanding of neurological conditions. That could lead to more accurate diagnoses, better-informed treatment plans and a deeper understanding of brain health.

Subsense said the bidirectional platform could record and modulate brain activity without surgical implants. Its nanoparticles are administered nasally to cross the blood-brain barrier. The system could avoid the risks and costs associated with surgically invasive electrodes or brain chips.

“We are developing a new kind of neural interface, which integrates seamlessly with the human body,” said Tetiana Aleksandrova, Subsense Co-founder and CEO. “This bio-integrated approach is fundamentally enhancing safety and expanding accessibility.”

In addition to the funding, the company recently opened a new laboratory and engineering facility in Palo Alto. Its technology portfolio spans nanoparticle chemistry, magnetic signal transduction, and proprietary neural decoding algorithms aimed at safe, reversible, and high-fidelity brain data capture.

Filed Under: Brain-Computer Interface (BCI), Business/Financial News, Funding Roundup, Health Technology, Neurological Tagged With: Subsense

More recent news

  • Boston Scientific continues to make progress on cyberattack recovery
  • Edwards Lifesciences, Medtronic score CMS win for TAVR
  • Stryker still working through cyberattack after-effects, stock down more than 10% this week
  • Siemens Healthineers completes $44M R&D, manufacturing site expansion
  • Next-gen Apple Watch Ultra 4 includes new health features

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy